Weekly Recap: Q2 beat and NY approval at University of Rochester Medicine

Bionano Genomics, Inc. (NASDAQ:BNGO) beat Q2 FY26 revenue guidance with $8.2M, raised FY26 revenue to $31—33M and guided FY27 to $50—54M with near—breakeven EBITDA by Q4 FY27 while cutting cash OPEX to $1.2M and retiring JGB debt as New York clears clinical use of its optical genome mapping at Univ…